20
Jul
2009
Posted in I - Series C, Q - 3Q09, R - WEST, X - Immunology, X - Metabolism, X - Pain, XX - CA
Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.